Tilray Inc (NASDAQ:TLRY - Get Free Report) was the recipient of unusually large options trading activity on Tuesday. Traders purchased 67,046 call options on the stock. This is an increase of 88% compared to the typical daily volume of 35,633 call options.
Institutional Trading of Tilray
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Prospect Financial Services LLC acquired a new position in shares of Tilray in the second quarter valued at approximately $26,000. Signature Estate & Investment Advisors LLC acquired a new position in Tilray in the 2nd quarter valued at approximately $29,000. Jeppson Wealth Management LLC bought a new position in shares of Tilray during the second quarter valued at $33,000. Vanguard Capital Wealth Advisors acquired a new position in shares of Tilray during the second quarter worth $34,000. Finally, HBK Sorce Advisory LLC bought a new stake in shares of Tilray in the first quarter worth $37,000. Institutional investors own 9.35% of the company's stock.
Wall Street Analyst Weigh In
Separately, Roth Mkm decreased their target price on Tilray from $2.00 to $1.75 and set a "neutral" rating on the stock in a report on Friday, October 11th.
View Our Latest Analysis on Tilray
Tilray Price Performance
NASDAQ:TLRY traded up $0.13 during trading hours on Tuesday, reaching $1.71. 51,535,151 shares of the company were exchanged, compared to its average volume of 25,121,730. The business has a 50 day moving average of $1.73 and a 200 day moving average of $1.81. Tilray has a 1-year low of $1.45 and a 1-year high of $2.97. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.47 and a quick ratio of 1.57. The company has a market capitalization of $1.54 billion, a P/E ratio of -5.93 and a beta of 2.13.
Tilray (NASDAQ:TLRY - Get Free Report) last issued its earnings results on Thursday, October 10th. The company reported ($0.04) EPS for the quarter, hitting the consensus estimate of ($0.04). Tilray had a negative return on equity of 2.00% and a negative net margin of 26.79%. The firm had revenue of $200.00 million during the quarter, compared to the consensus estimate of $218.70 million. During the same quarter in the previous year, the firm earned ($0.10) earnings per share. The business's quarterly revenue was up 13.0% on a year-over-year basis. Research analysts forecast that Tilray will post -0.14 EPS for the current year.
About Tilray
(
Get Free Report)
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.
See Also
Before you consider Tilray, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tilray wasn't on the list.
While Tilray currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
